苯达莫司汀联合地塞米松治疗复发/难治性系统性轻链淀粉样变性:II期研究结果
该II期多中心试验纳入31例既往接受过至少1线治疗的持续或进展性AL淀粉样变性患者,评估苯达莫司汀联合地塞米松的疗效与安全性。
要点
- 苯达莫司汀联合地塞米松在经治AL淀粉样变性中57%达血液学PR或更好
核心结论
- 苯达莫司汀联合地塞米松对既往治疗过的AL淀粉样变性患者是一种可行治疗方案,具有实质性疗效且毒性有限。
研究设计与样本
- II期多中心试验纳入31例既往接受过至少1线治疗后持续或进展的AL淀粉样变性患者。
- 苯达莫司汀第1、2天100 mg/m2静脉给药,联合每周40 mg地塞米松,28天为一周期,直至疾病进展或完全血液学缓解后再用最多6周期。
- 主要终点为部分血液学缓解(PR)或更好的比率。
主要发现
- 患者中位接受4周期(范围2-12周期)治疗,57%达到PR或更好(11%完全缓解,18%非常好的部分缓解)。
- 24例有可测量器官受累的患者中,总体器官缓解率为29%。
- 中位无进展生存11.3个月(95%CI 5.0-15.4个月)。
关键数值与推荐
- 血液学缓解率:PR或更好57%,完全缓解11%,非常好的部分缓解18%。
- 器官缓解率:可测量器官受累患者中29%。
- 中位总生存18.2个月(95%CI 11.3-43.8个月),中位无进展生存11.3个月(95%CI 5.0-15.4个月)。
临床怎么用
- 对于既往治疗过、治疗选择有限的AL淀粉样变性患者,可考虑苯达莫司汀联合地塞米松方案。
- 治疗中需监测骨髓抑制、乏力及恶心/呕吐等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: No established treatments exist for relapsed/refractory systemic light-chain (AL) amyloidosis. Bendamustine has shown potential in the treatment of multiple myeloma. We conducted a phase II, multicenter trial to assess the efficacy and safety of bendamustine with dexamethasone (ben-dex) in patients with persistent or progressive AL amyloidosis after ≥ 1 prior therapy. METHODS: The trial enrolled 31 patients who received bendamustine on days 1 and 2 (100 mg/m2 intravenously) with 40 mg of weekly dexamethasone in 28-day cycles until disease progression or up to 6 cycles after complete hematologic response. The primary objective was the rate of partial hematologic response (PR) or better. RESULTS: Patients received a median of 4 cycles (range, 2-12 cycles) with 57% of patients achieving a PR or better (11% complete response, 18% very good PR). The overall organ response was 29% among the 24 patients who had measurable organ involvement. Treatment was well tolerated with no grade 5 treatment-related adverse events (AEs). Sixty-five percent of patients had a therapy-related grade 3-4 AE. The most common AEs included myelosuppression, fatigue, and nausea/vomiting. The median overall survival was 18.2 months (95% CI, 11.3 to 43.8 months), and hematologic response was associated with prolonged survival (P = .0291). The median progression-free survival was 11.3 months (95% CI, 5.0 to 15.4 months). CONCLUSION: Overall, ben-dex is a viable treatment option with substantial efficacy and limited toxicity for patients with pretreated AL amyloidosis who have limited therapeutic options. This trial was registered at (ClinicalTrials.gov identifier: NCT01222260).
引用
- Lentzsch S, Lagos GG, Comenzo RL, et al. Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study. J Clin Oncol. 2020. PMID: 32083996. doi:10.1200/JCO.19.01721
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。